We have locations identified in Israel to perform a planned Phase 2 clinical trial for plaque psoriasis in mid-2008, subject to approval of the Ministry of Health in Israel, added Dr. Berkowitz. The Ministry of Health is already familiar with ALT-2074 since it approved its use in our ongoing study 203rd Based on our current timeline, assuming timely receipt of regulatory approval, we hope to give results of the study in the fourth quarter of 2008 levitra reviews . We expect that this psoriasis program will help to and contribute and help. ‘s Long-term growth of Synvista Therapeutics while opening a new potential market opportunity for our product compounds out-licensing This announcement by Synvista further evidence of the value of the broad antioxidant drug and dietary supplement portfolio of Oxis International, said Marvin S. Hausman, Pres / CEO. Oxis wants to pursue out-licensing compounds for specialized portfolio company in the field of bioactive substances and antioxidants. .
More information about Oxis, BioCheck and their products and services as well as current SEC may by visiting and obtain.
‘It was a big switching from default anti-infective research that typically covered with the pathogens easily replicated in culture,’explains Dr. ‘In our experiments, we wanted to see whether biochemical operators the infectious process could be could be inoperative would yield in the customary in vitro setting. ‘.
How do the bacteria are do it, although surrounded by many the more acidic phagocytic vacuoles? To find out, the team used a sort of genetic fine tuning in that effectively disable M.tuberculosis ‘ capability of producing a key protein lie of their membrane – known a protease Rv3671c.